ATHA vs. ABVC, CUE, GANX, ATRA, RNXT, RENB, ZIVO, QNTM, CRVO, and AADI
Should you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include ABVC BioPharma (ABVC), Cue Biopharma (CUE), Gain Therapeutics (GANX), Atara Biotherapeutics (ATRA), RenovoRx (RNXT), Renovaro (RENB), ZIVO Bioscience (ZIVO), Quantum Biopharma (QNTM), CervoMed (CRVO), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry.
Athira Pharma vs. Its Competitors
Athira Pharma (NASDAQ:ATHA) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.
Athira Pharma has a beta of 2.99, suggesting that its stock price is 199% more volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.
In the previous week, ABVC BioPharma had 2 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for ABVC BioPharma and 1 mentions for Athira Pharma. ABVC BioPharma's average media sentiment score of 0.57 beat Athira Pharma's score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the news media.
57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 22.1% of Athira Pharma shares are owned by company insiders. Comparatively, 17.1% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Athira Pharma has a net margin of 0.00% compared to ABVC BioPharma's net margin of -963.46%. ABVC BioPharma's return on equity of -29.62% beat Athira Pharma's return on equity.
Athira Pharma presently has a consensus price target of $11.25, suggesting a potential upside of 2,572.21%. Given Athira Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Athira Pharma is more favorable than ABVC BioPharma.
ABVC BioPharma has higher revenue and earnings than Athira Pharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Athira Pharma and ABVC BioPharma tied by winning 7 of the 14 factors compared between the two stocks.
Get Athira Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Athira Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ATHA) was last updated on 7/10/2025 by MarketBeat.com Staff
